Figure 5.

Anti-LIGHT mAb and RANK-Fc inhibit the osteoclast formation in cultures from MM active bone disease responders, relapses, and in progressive disease patients. Multinucleated and TRAP⁺ cells, differentiated from peripheral blood mononuclear cell (PBMC) cultures of responders, relapses and progressive disease (PD) patients with active bone disease (BD), were evaluated after 21 days of culture in the presence of anti-LIGHT mAb or RANK-Fc or control anti-IgG mAb. The treatment with anti-LIGHT mAb (A) or RANK-Fc (B) induced a dose-dependent inhibition of osteoclastogenesis, which was not affected by the control anti-IgG mAb. The number of multinucleated and TRAP⁺ cells, identified as OCs, are represented in the graphs as mean ± SE of all experiments performed in quintuplicate. P < 0.001 for comparison of all groups (one-way ANOVA on ranks), *p < 0.05 vs. CTRL (with Tukey post-hoc test).